| Outcome Measures: |
Primary: Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 2.5 mg), Target range is defined to be between 3.9 and 10.0 mmol/L of placebo on closed-loop system vs. empagliflozin 2.5 mg ono closed-loop insulin system., 10 days|Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg), Target range is defined to be between 3.9 and 10.0 mmol/L of placebo on closed-loop system vs. empagliflozin 5 mg ono closed-loop insulin system., 10 days | Secondary: Percentage of time spent in the following ranges of glucose levels between 3.9 and 7.8 mmol/L, 10 days (for each intervention)|Percentage of time spent in the following ranges of glucose levels: below 3.9, 3.3 and 2.8 mmol/L, 10 days|Percentage of time spent in the following ranges of glucose levels: above 7.8, 10, 13.9, and 16.7 mmol/L, 10 days|Average glucose level, 10 days|Percentage coefficient of variation of glucose levels, 10 days|Quality of life measure by Type 1 Diabetes Distress Scale: score is the average of 28 items from 1 to 6 (higher score indicates more emotional distress), 10 days|Quality of life measure by Hypoglycemic Fear Survey - II: score is the average of 33 items from 1 to 5 (average of higher scorer equates to more distress), 10 days|Quality of life measure by INSPIRE (Insulin delivery Systems: Perceptions, Ideas, Reflections and Expectations) questionnaire for adults: score is the average of 22 items from 1 to 5 (average of higher scorer equates to more distress), 10 days|Total daily insulin dose, 10 days|Average point-of-care ketone level per intervention, 10 days|Rise in ketone level between interventions, 10 days
|
